Online Makale
Online Hizmetlere Toplu BakışHaydarpasa Numune Egitim ve Arastirma Hastanesi Tip Dergisi
Haydarpasa Numune Med J. 2023; 63(2): 126-131 | DOI: 10.14744/hnhj.2021.59265 | |||
The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial TumorsAylin Gönültaş1, Güray Kılıç1, Fügen Vardar Aker1, Mehmet Aliustaoğlu21Department of Pathology, Istanbul Haydarpasa Numune Training and Research Hospital, Istanbul, Türkiye2Department of Onkology, Kütahya University of Health Sciences, Kütahya, Türkiye INTRODUCTION: Overexpression and the amplification of proto-oncogenic c-erythroblastic oncogene B (c-erbB-2) (HER-2/neu) encode transmembrane growth factor glycoprotein and are a part of the type I receptor tyrosine-protein kinase. It is known to play a role in the treatment of breast and stomach carcinomas. C-erbB-2 overexpression and amplification in urothelial carcinomas have also been demonstrated in many studies. However, possible treatment options and prognostic values are still not sufficiently defined. This study aims to determine the overexpression rate of c-erbB-2 in urothelial carcinomas. In addition, we sought to determine if there was a relationship between c-erbB-2 overexpression and clinical-pathological prognostic factors, such as histological grade, pathological stage, lymph node and distant organ metastasis, and survival time. Aylin Gönültaş, Güray Kılıç, Fügen Vardar Aker, Mehmet Aliustaoğlu. The Effect of C-erbB-2 Expression on Clinical-Pathological Prognostic Factors and Survival Ratios in Urothelial Tumors. Haydarpasa Numune Med J. 2023; 63(2): 126-131 Sorumlu Yazar: Aylin Gönültaş, Türkiye |
|